Abstract Introduction
Introduction
In this study, we used a massive parallel sequencing technology to investigate the cellular small RNA (sRNA) operating in peripheral blood mononuclear cells (PBMCs) of the Human T-lymphotropic virus type I (HTLV-I) infected asymptomatic subjects with a monoclonal and polyclonal rearrangement of the T-cell antigen receptor γ-chain.
Materials and Methods
Blood samples from 15 HTLV-1 asymptomatic carriers who were tested for clonal TCR-γ gene (seven and eight subjects presented monoclonal and polyclonal expansion of HTLV-1 infected cells, respectively), and were submitted to Illumina for small RNA library construction. sRNA libraries were prepared from cryoperserved PBMCs using TrueSeq Small RNA Library Preparation Kit (Illumina). The sRNA-Seq reads were aligned, annotated, and profiled by different bioinformatics tools.
Results
Through bioinformatics analysis, we identified a total of 494 known sRNAs and 120 putative novel sRNAs. Twenty-two known and 15 novel sRNA showed a different expression (>2-fold) between the asymptomatic monoclonal (ASM) and asymptomatic polyclonal carriers (ASP). The hsa-mir-196a-5p was the most abundantly upregulated micro RNA (miRNA) and the hsa-mir-133a followed by hsa-mir-509-3p were significantly downregulated miRNAs with more than a three-fold difference in the ASM than ASP group. The target genes predicted to be regulated by the differentially expressed miRNAs play essential roles in diverse biological processes including cell proliferation, differentiation, and/or apoptosis.
Introduction
Human T-lymphotropic virus type I (HTLV-I) is an oncogenic human retrovirus that was first isolated from a T-cell line, HUT102, that had been obtained from a patient with adult T-cell leukemia/lymphoma (ATLL) [1] . Globally, there are an estimated 5-10 million individuals who carry the HTLV-I, with the important caveat that the prevalence remains barely unknown in many areas of the world [2] . The disease burden is unevenly distributed, with a higher incidence of the disease particularly in southwest Japan, the Caribbean islands, South America, and portions of Central Africa [3] . Infection with HTLV-I may result in a spectrum of clinical manifestations, ranging from asymptomatic infection to a number of human disorders, most notably a malignant ATLL and a chronic progressive neuromyelopathy, termed HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [4] . The majority of HTLV-I-infected individuals remain asymptomatic for life, while some individuals progress to a pre-leukemic phase that is characterized by small numbers of circulating leukemic cells in the peripheral blood, skin lesions, and a lack of involvement of other organ systems [5] . Only 2.5% to 5% of the virus carriers eventually develop ATLL after a long asymptomatic period [6, 7] . The reason why some people develop the disease, whereas others remain healthy, is likely dependent on both host-related and virus-related factors [8] . Available evidence from molecular studies indicates that the impairment of various cellular functions by viral genes (e.g., tax and HBZ), genetic and epigenetic changes including DNA methylation, and the host immune system may contribute to the leukemogenesis of ATLL [9] [10] [11] . Despite the effective immortalization of the T cells, the markedly prolonged incubation period (>30 years) prior to the onset of ATLL, suggests an additional acquisition of genetic changes beside the viral infection to contribute to the pathogenesis [12] .
Infections with HTLV-1 are expected to produce an initial polyclonal T-cell proliferation followed by a monoclonal malignant transformation in asymptomatic HTLV-1 carriers before the diagnosis of Adult T-cell Leukaemia/Lymphoma becomes evident. HTLV-1carriers who have monoclonal integration of HTLV-1 provirus DNA in their mononuclear cells are suggested to be a high-risk group for development of ATLL, but their prognosis varies from being stable long-term carriers to experiencing the development of ATLL [13] [14] [15] [16] . Carvalho and Da Fonseca Porto [17] also found a correlation between monoclonal integration of provirus DNA and abnormal lymphocytes in peripheral blood, with a trend for greater severity of the parasitic infection.
Over the past several years, some studies have provided significant evidence to support transcription of many non-protein-coding regions of the mammalian genome [18] , yielding a complex network of transcripts that include tremendous numbers of noncoding RNAs (ncRNA). These molecules play significant roles in normal biological processes and in a variety of human diseases [19] . Within this diverse menagerie of ncRNA, small RNAs (sRNAs), have emerged as potential posttranscriptional regulators of gene expression in both eukaryotes and prokaryotes [20] . Because these molecules are highly complex in terms of structural diversity and function, their families have been grouped into structural and regulatory ncRNA [21] . The structural ncRNA includes transfer RNA (tRNA) and ribosomal RNA (rRNA), as well as other small but stable noncoding RNAs, such as small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), small cytoplasmic RNA (scRNA), Ribonuclease P (RNase P), mitochondrial RNA processing (MRP) RNA, signal recognition particle (SRP) RNA, and telomerase RNA. Regulatory ncRNAs include microRNAs (miRNAs), PIWIinteracting RNAs (piRNAs), and long ncRNAs (lncRNAs) [22] . The miRNAs are perhaps the single best-understood subclass. They are typically 18-25 nucleotides (nt) in length, single-stranded RNAs that have emerged as principal post-transcriptional regulators of gene expression and play a vital role in several cell processes including cell proliferation, differentiation, apoptosis, embryonic development, and tissue differentiation [23, 24] . The mature molecules of miRNAs are assembled into ribonucleoprotein complexes called miRNA-induced silencing complexes (RISC), which inhibits gene expression by perfect complementary binding, for mRNA degradation, or imperfect binding at the 3'UTR region, to inhibit translation [25] . The rigid control of miRNA expression is critically important to maintain cells in normal physiological states [26] , while overexpression of miRNAs has been associated with the occurrence and development of various diseases [25, 27] . It has been proven that oncogenic (onco-miRs) and tumor-suppressor (TS-miRs) miRNAs exert control over important cell cycle components and thus results in either acceleration or deceleration of the cell cycle [28] [29] [30] .
In theory, dysregulation of host cells miRNAs by HTLV-1 might influence the development of ATLL. Indeed, some reports attest to the critical role of cellular miRNA to proliferation and survival of HTLV-1-infected T-cells. Hybridization-based methodologies, such as microarray and PCR-based assays have been used thus far to identify and profile the cellular miRNAs in HTLV-1 infected cell lines [31, 32] . The study by Pichler et al. [33] , who first used quantitative PCR to study the interconnections between HTLV-1 and cellular miRNAs, confirmed that HTLV-1 transforms host cells by inducing dysregulation of the expression of specific miRNAs, including miR-146a, which is upregulated by Tax protein (an oncoprotein of HTLV-1).
Subsequently, other expression studies revealed both up-and downregulation in a number of miRNAs in HTLV-1/ATLL cell lines and primary ATLL cells [34, 35] .
Recently, Ruggero and colleagues [36] employed massive sequencing to identify the repertoire of microRNAs and tRNA fragments (tRFs) expressed in HTLV-1-infected cells compared to normal CD4+ T cells. Most of the previous studies mainly focused on expression of specific or diverse miRNA in HTLV-1 infected cell lines, while few studies have focused on determining the expression profiles of sRNAs isolated from human blood samples. Thus, it would be clinically relevant to investigate early gene regulatory mechanisms associated with cell transformation in HTLV-1 asymptomatic patients with monoclonal expansion features.
In this study, we employed Illumina massive parallel sequencing technology to comprehensively characterize the sRNA expression profiles in the peripheral blood mononuclear cells (PBMCs) of HTLV-1 infected asymptomatic subjects with monoclonal (ASM) and polyclonal (ASP) T cell expansions. Our results revealed 494 known sRNAs and 120 putative novel sRNAs. Moreover, 23 known and 15 novel sRNA showed different expressions (>2-fold) between the ASM and the ASP groups.
The data obtained in this study provides considerable insight into understanding the expression characteristic of sRNAs in HTLV-1 carriers with monoclonal T cell population. Differentially expressed sRNAs described here may be associated with the transformation of T cells.
Materials and Methods

Patients' characteristics and sample preparations
Peripheral blood samples were initially collected from a relatively large group of asymptomatic HTLV-1 carriers (n = 367). Of these subjects, 15 carriers were selected for this study on the basis of clonality results and classified to ASM (n= 7) and ASP (n=8). The samples were collected after approval by the institutional health research ethic authority and the signing of written informed was obtained from all individual participants included in the study. Isolation of PBMCs was carried out by FicollHypaque (Amersham, Upsala, Sweden) density centrifugation, washed twice in RPMI 1640 with 10 % fetal calf serum, and stored in liquid nitrogen until use. A summary of the clinical characteristics of study subjects is shown in Table 1 .
Genomic DNA and RNA extraction
Genomic DNA was extracted from PBMCs using the QIAamp blood kit (QIAGEN, Tokyo, Japan). The miRNeasy Mini Kit (Qiagen, Hilden, Germany) in conjunction with the TRIzol (Life Technologies, USA) procedure were used to extract total RNA and sRNA following the manufacturer's protocols. Briefly, 700 μ L of TRIzol was added to 200 μ L of cryoperserved PBMCs followed by incubation at room temperature for 5 min.
Chloroform (Sigma-Aldrich, St. Louis, MO, USA) was added, and the samples were vortexed and incubated at room temperature for 5 min followed by centrifugation at 12,000×g for 15 min at 4° C. The aqueous phase containing RNA was transferred to a new tube and isopropanol (Fisher-Scientific, Thermo Fisher Scientific, Waltham, MA, USA) was added. The samples were incubated at room temperature for 10 min followed by centrifugation at 12,000xg for 15 min at 4° C. The pellet was washed with 75% Ethanol (Sigma-Aldrich), air-dried, and resuspended in 20 
HTLV-1 proviral load determination
The extracted DNA was used as a template to amplify a 97-bp fragment from the HTLV-1 tax region using previously published primers [37] and protocol [38] .
Amplification and analysis were performed with the Applied Biosystems 7500 real-time PCR system. The standard curves for HTLV-1 tax were generated from MT-2 cells of log 10 dilutions (from 10 5 to 10 0 copies). The threshold cycle for each clinical sample was calculated by defining the point at which the fluorescence exceeded a threshold limit. Each sample was assayed in duplicate, and the mean of the two values was considered the copy number of the sample. The HTLV-1 proviral load was calculated as the copy number of HTLV-1 (tax) per 1000 cells = (copy number of HTLV-1 tax)/(copy number of RNase P gene/2)×1000 cells. The method could detect one copy per 10 3 PBMCs.
Analysis of T cell receptor yTCR genes
A DNA-based polymerase chain reaction (PCR) of rearranged yTCR genes was performed according to the previously described protocol [39] . All patients' PCR products were analyzed with the 3130 ABI Prism capillary electrophoresis equipment. 
sRNA Data analysis and interpretation
Base calling, demultiplexing, and trimmed FASTQ files were generated using the MiSeq reporter. Only high quality reads with score >30 on the Sanger scale were considered for further analysis. The reads were aligned against the whole genome build:
hg19 using Strand NGS v3.1. The later software package was also used for analysis of novel molecule discoveries and interpretations. The distributions of the sRNA data in each clinical condition were conducted according to the quantile normalization algorithm, with a baseline transformation set to the median of all samples. Novel sRNA were discovered and classified by the decision tree method with three-fold validation accuracy using model previously described by Langenberger et al. [41] . Additionally, only sRNA sequences meeting the minimum read coverage criterion of >20 were considered as novel or known sRNA and were included in further analyses. sRNAs with fold change more than 2.0 were considered to be differentially expressed. All the sRNA raw data generated by MPS has been deposited to the Zenodo repository.
Functional annotation and pathway analysis of miRNA target genes
The target genes from differentially expressed miRNAs were predicted by PicTar, TarBase microRNAorg databases. Pathway analysis was carried out for a functional analysis of mapping genes to KEGG pathways [42] . Prediction was performed by using DIANA-microT-CDS [43] . The biological functions of these target genes were determined by the enriched GO analysis (false discovery rate p-value <0.05).
Results
Patient Characteristics
The characteristics of the subjects in both groups are shown in Table 1 . All eight participants within the ASP group were female and the median age was 58 years (range, 31-80 years). Six females and one male were assigned to the ASM group and the median age of the entire group of subjects was 61 years (range, 28-74 years). HTLV-1 proviral load levels varied from one copy to 208 copies/10 3 PBMCs in the ASP group and varied from undetectable to 327 copies/10 3 PBMCs in the ASM group (two-tailed P value = 0.7).
Description of whole genome sRNA-sequencing data from both groups
Illumina MPS revealed a total of 130,415,317 reads. After removal of low quality data and reads that failed vendor`s QC, 125,435,316 reads were retained. The filtered sRNA reads on quality metrics for each sample used in the alignment to the human genome sequence dataset are shown in Table 1 exonic RNAs, scRNAs, snRNAs, snoRNAs, tRNAs, and others. Next, we evaluated the location of these tags on the chromosome. In the majority of samples from both groups, most of the unique tags were located on chromosome 3, 8, 12, and 19 (table S1). The
Illumina MPS yielded 614 sRNA molecules, of which 494 sequences were derived from known sRNA, and 120 were novel sRNA. Of the 494 known sRNA, 219 were miRNA, 30 scRNA, 9 scRNA_pseudogene, 162 snoRNA, 23 snRNA, and 51 tRNA (table S2).
Of the 120 novel genes, 25 were novel miRNA, 50 snoRNA, 3 snRNA, 9 tRNA, and 33 unknown (table S3) . Considering -3p and -5p mature forms of miRNA, our analysis revealed a total of 2104 mature miRNA, of which 22 had had greater than a two-fold change in expression (table 2).
Characteristics of the abundant known and novel sRNAs
Among the 494 known sRNAs identified in this study, 52 sRNAs were found to be differentially expressed (>2-fold) between the ASM group and ASP group, which accounted for 8.5% (52/614) of all the sRNAs investigated (table S4). Clustering by group was not noted in the hierarchal combined tree of the 52 significantly differentially expressed sRNA levels as shown in figure 2. Of these 52 sRNAs, 50 were upregulated and two were downregulated in the ASM group. The upregulated sRNA includes three miRNA, 10 scRNA, one scRNA_pseudogene, 21 snoRNA, one snRNA, and 14 tRNA.
On the other hand, the down-regulated entities include only two miRNA. Of the highly expressed sRNAs, SNORD45, SNORD45B, hsa-mir-196a-1, hsa-mir-196a-2, and SCARNA5 were the top five most abundantly expressed sRNA in PBMCs of the ASM group, among which, SNORD45 had greater than 5.7 fold changes in expression (table   S4) . The most abundantly downregulated sRNAs in PBMCs of the ASM group were hsa-mir-133a-1 and hsa-mir-133a-2, which showed more than 3.8 fold changes in the ASM when compared to the ASP group (table S4) . Further, of the 22 mature miRNAs that exhibited a >2-fold difference in expression in the PBMCs of the ASM compared to the ASP group, 11 miRNAs were upregulated and 11 were downregulated (table 2).
The hierarchical clustering analysis of these miRNAs showed distinct patterns of miRNA expression levels between ASM and ASP groups (Figure 3) . The hsa-mir196a-5p was the most abundantly upregulated miRNA and the hsa-mir-133a followed by hsa-mir-509-3p were the significantly downregulated miRNAs with more than a three-fold difference in the ASM than the ASP group. Of the 120 novel sRNA described in this study and shown in table S3, 15 were found to be differentially expressed (>2-fold) between the ASM group and ASP group, which accounted for 2.4% of all the sRNAs investigated. Of these, 14 were upregulated and one was downregulated in the PBMCs of the ASM group when compared to the ASP group. Of the upregulated novel sRNAs, four were snoRNA, one miRNA, one tRNA, and eight were unknown while the unique downregulated gene was snoRNA ( Table 3) .
GO Analysis of the Target Genes of the Differentially Expressed sRNAs
The role of a miRNA is ultimately defined by the genes that it targets and by its effect on the expression of those genes. To discover these functions, the target genes of the two groups of the mature significantly expressed miRNAs were predicted using the three programs PicTar, TarBase, and microRNAorg databases. The intersection of these three programs was used to reduce the false-positive rate. As shown in Table S5 , a pvalue cutoff of 0.001 was selected to predict nine target genes. The most significantly selected candidate target gene FGD6 is regulated by 13 of the 27 mature significantly expressed miRNAs. The second most selected target gene is the CUGBP Elav-like family member 6 (CELF6) gene, which is regulated by 10 of the 27 mature significantly expressed miRNAs. To identify the actual regulatory functions of the miRNAs, the GO annotation of the target genes was performed on the list of predicted target miRNAs that corresponded with altered miRNAs in the ASM group at p value <0.05. The results from this analysis revealed no significant GO enrichments for the differentially expressed genes predicted from the known miRNAs. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of target genes were assigned using mirPath v.3 in DIANA tools webserver. KEGG pathway annotation revealed that 3044 background genes were annotated for 56 biological functions. The top five pathways were Adherens junction, Proteoglycans in cancer, Axon guidance, Morphine addiction, and Prion diseases.
Discussion
In this study, we used Illumina high-throughput sequencing technology to analyse the global expression of non-coding RNome in PBMCs of HTLV-1 infected asymptomatic subjects with monoclonal and polyclonal rearrangement of the T-cell antigen receptor γ-chain. Our results revealed 52 significantly differentially expressed sRNAs in the ASM group compared with the ASP subjects. Furthermore, we identified 15 novel sRNA exhibited much higher expression levels in ASM patients than reads in ASP. Eleven of the 22 differentially expressed mature miRNA were up-regulated while the other 11
were down-regulated in the ASM group. Out of the 22 most dysregulated miRs, we selected the most significantly up-regulated miRs (miR-196a-5p) and down-regulated miRs (miR-133a, miR-625-3p, and miR-3120-3p) assuming that the measurement of these miRs could discriminate ASM from ASP patients and that the dysregulation of these miRs in ASM may represent early markers for T cell transformation with unknown functional consequences.
We searched for putative target genes associated with enhancement of cellular transformation. miR-3120-3p was down-regulated (fold change = −3.154) in the ASM group, and was negatively correlated with diverse putative target genes such as the SLC33A1, tripartite motif containing 27 (TRIM27), XPO1, CASKIN2, and CELF6. The TRIM27 is a member of a large family of proteins that function as Really Interesting New Gene [82] E3 ubiquitin ligases. The TRIM27 has the ability to inhibit the class II phosphatidylinositol 3 kinase C2β activity, resulting in decreased KCa3.1 channel activity and decreased TCR-stimulated Ca2+ influx and cytokine production, thereby identifying TRIM27 as a unique negative regulator of CD4 T cells [84] .
There are few microarrays studies that have also characterized the miRNA expression profiles in HTLV-1/ATLL cell lines and ATLL patients [33] [34] [35] 85] ; however, it is difficult to compare their results with our study due to the different methods employed, different research designs, and different target population.
Our study has several limitations, particularly its retrospective design, and lack of a control non-infected group. Additionally, few samples were included, and no validation study was performed. In spite of these caveats, the current study unravels a number of known and novel subsets of dysregulated sRNA including signature in the PBMCs of the ASM group. The aberrant expression of sRNAs paves the way for assessment of their mechanistic roles and clinical utilities as biomarkers, prognostic indicators, and/or therapeutic targets in early HTLV-1 pathogenesis.
In conclusion, significantly differentially expressed sRNAs including miRNAs and their target genes between ASM and ASP were identified by means of MPS technique. These newly identified miRNAs and target could have unexplored functions in HTLV-1 pathogenesis. Therefore, further investigation of a large population of leukaemia patients using well-matched control groups and sequential samples will be required to elucidate the possible pathogenic impact of these ncRNA molecules in HTLV-1 infection. 3-Hierarchical cluster analysis of miRNAs differentially expressed comparing ASM vs ASP samples. Hierarchical clusters were generated using the Euclidean distance and Pearson correlations of miRNA expression patterns. The up-(red) and down-regulated (blue) miRNAs were scaled according to the depicted color code. Table S1 : Distribution of the small RNA massively sequencuing reads according to the chromosomes Table S2 : A full list of all known small RNAs identified in this study Table S3 : A full list of all novel small RNAs identified in this study Table S4 : List of small RNAs differentially expressed in asymptomatic HTLV-1 infected subjects with monoclonal (ASM) vs subjects with polyclonal T cell expansion (ASP) 
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